Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Scientists discover how brain cells die in Alzheimer’s
https://www.msn.com/en-us/news/world/scientists-discover-how-brain-cells-die-in-alzheimer-s/ar-AA1gKGni
Scientists in the UK and Belgium think they have figured out how brain cells die in Alzheimer's disease…
But the team, writing in the journal Science, connect the abnormal proteins that build up in the brain with "necroptosis" - a form of cellular suicide…
They say abnormal amyloid starts to build up in the spaces between neurons, leading to brain inflammation, which the neurons do not like. This starts to change their internal chemistry.
Tangles of tau appear and the brain cells start producing a specific molecule (it's called MEG3) that triggers death by necroptosis. Necroptosis is one of the methods our bodies normally use to purge unwanted cells as fresh ones are made.
The brain cells survived when the team were able to block MEG3.
…The answers came from experiments where human brain cells were transplanted into the brains of genetically modified mice. The animals were programmed to produce large quantities of abnormal amyloid.
There has been recent success in developing drugs that strip amyloid out of the brain and they mark the first treatments to slow the destruction of brain cells.
[Will the continuation of the Brave study at U. Wisconsin illustrate that Vascepa has been or can be used to treat Alzheimer's Disease and its biomarkers per the above or similar paradigm?]
https://www.science.org/doi/10.1126/science.abp9556
***********************************************
The above is from Biowatch on the BioTech Values board a few day ago. I added the question in [...].
Today(CNBC-TV at ~ 2:45 pm) an analyst commented on that recent trial of Paxlovid that you refer to, adding that he didn’t see how PFE was going to accrue sufficient revenue to replace the revenue PFE is likely to lose in the next few years from current drugs losing exclusivity from patent expirations.
PFE continues to look for small, bolt-on acquisitions in addition to SGEN. PFE continues to market/sell Amarin’s Vascepa to general practitioners in Canada in collaboration with HLS. Vascepa has been shown to reduce the risk of death from cardiovascular disease; CVD kills more people world-wide than cancers( 1 drops dead from CVD every 38-40 seconds). A clinical trial (BLAZE) completes this coming week that has an Alzheimer’s indication. Stay tuned.
JAMA Original Investigation, titled “Sedentary Behavior and Incident Dementia Among Older Adults”[doi:10.1001/jama.2023.15231] reports that sedentary behavior is associated with cardiometabolic disease and mortality but its association with dementia is unclear. The authors concluded: Among older adults, more time spent in sedentary behaviors was significantly associated with higher incidence of all-cause dementia. Further research is needed to determine whether the association between sedentary behavior and dementia is causal.
(draichle@usc.edu).
Approval in Australia, relying on Reduce-It, Marine and Anchor clinical trials. The document is ~ 44 pages, worth reading, IMO, if only to refresh memory. Discussion of the “MO issue” is interesting in finding MO in the placebo arm does not diminish the effect of EPA.
In that "healthy cohort", the researchers/investigators are predicting that some of that cohort will develop signs of AD in light of parental history risk factor, etc.
It is in those members of the cohort who become "unhealthy" that the researchers will assess whether IPE improves cognitive performance, etc. compared to placebo. Would anyone investigate whether IPE would improve cognitive ability of normally healthy people?
I wonder whether Dr. Carlsson’s sojourn as chairperson of that HHS advisory panel on AD has ended or been extended. Her appointment was scheduled to end in the summer of 2023, as I recall.
GSAT? See recent PRs re QCOM, AAPL and new CEO at GSAT.
We received 3 nearly identical notices from DOJ in District of Columbia in the past few days. Does anyone know whether Judge Davila will make his courtroom hearing accessible to all members of the public via video and/or audio?
In what category is OmegaXL, a pain and inflammation relief medication sold OTC that continues to be heavily advertised on TV? I think I recall Amarin lost(?) a suit against the purveyor of that medication. Vascepa seems to have no label(expansion?) for pain/inflammation relief indication.
I showed your message to my M.D. spouse before she left for her own retina group eye appointment. We both wish you a quick recovery. Neither of us have been infected yet, despite many crowded conditions at parties, concerts at Kennedy Center, grocery shopping and the like. We both have had our respective vaccines and 4-5 booster shots. Ten years of Vascepa for me; no Vascepa for her…yet.
We will keep your experience and treatment regimen in mind should our own circumstances dictate.
BTW, I picked up my 3- month supply of Vascepa today. A new message from our local CVS appeared on my receipt and prescription info form: “Insurance only covers the brand name version of this drug.” The message that insurance companies should derive from the settled HealthNet case seems to be taking effect.
Thanks. I had forgotten that plan/factor.
Who is “they” with a price target of $15?
MNK files for bankruptcy, per Dow-Jones.
Will the new SEC regulations that overhaul the MOA of private equity and hedge funds have any effect on the dealings
and transparency of Sarissa/Denner?
I haven’t looked at the court website lately, but it will post a day and time for arguments. Meantime, I have been more focused on our shares of NVDA, MSFT, AAPL, IBM, AMD and JNJ—and what is in store for the rest of our portfolios.
FWIW, CDMO now has a TipRank of 1, underperform. It remains our most profitable position in TDA; JNJ is our most profitable position, held in a different brokerage. We have a 250% gain on our 500 HALO shares.
Amarin CEO Patrick Holt acquired a total of 300,000 shares at an average price of $1.04, spending as an insider ~ $312,315. TDA news this morning, per Benzinga.
zip, do you mean FTC or DOJ antitrust, rather than FDA? Methinks FDA has nothing to do with approving PFE/SGEN merger/acquisition activity.
Do you wonder where those 15 pages of millions of institutional shares are going? Perhaps near a million more at 3:57 pm today? Are those shares being bought, already pledged or transferred to another unnamed entity, much like BMY acquired MEDX shares more than a decade ago? Is PFE the unnamed entity? Is Icahn, IEP, again entering historic activist mode?
See Zacks article on SGEN TDA news page today re PFE M/A activity.
Coincidently, our recent purchase of TOMZ shares finds its technology being used to disinfect the PFE Rocky Mount plant recently hit with tornado damage
GMAB reports strong DARZALEX sales, royalty revenue today. May account for increased CDMO share price today. Archived conference call will be available after 12:00 noon today: www.genmab.com/investors site
We like PLTR also. See BIGT, an ETF with 5 main holdings: AAPL, AMZN, GOOG and GOOGL, META and MSFT.
It would not surprise me to see NVDA replace NFLX which was dropped from the original "FAANG" stocks.
BIGT is a convenient, inexpensive way of keeping track of the main players in the AI space; we purchased our original shares at $25.92, and added at $28.17.
I was not aware of INVZ, jasbg. Thanks for the link; I'll add it to the watchlist. I did buy a small position in driverless auto technology company AUR in 11/2022 and 1/2023. UBER seems to be a believer in the AUR technology, recently increasing its equity position in the stock. See also VMAR, EVGO and especially GOEV, in which we purchased small positions in the past year. We diversify while AMRN matures ROW.
We have held 400 shares of DE [@$53.82, now $427.10] for many years, and watched its development of driverless farm machinery to plant and harvest crops. We saw the Raven technology developed in my hometown in S.Dak., and was hoping DE would buy it. CNHI bought it instead. We plan to visit the John Deere complex/pavilion on 8/09/2003 as one of our shore excursions offered by Viking as part of our Mississippi River cruise beginning 8/04/2023.
How about using excess capacity to produce cells for use in STKH's technology that has recently been introduced in the U.S.?
https://invest.ameritrade.com/grid/p/site#r=jPage/https://research.ameritrade.com/grid/wwws/research/stocks/summary?symbol=STKH&c_name=invest_VENDOR
https://invest.ameritrade.com/grid/p/site#r=jPage/https://research.ameritrade.com/grid/wwws/research/stocks/news/article?c_name=invest_VENDOR&docKey=100-205p4736-1
Re your "conspiracy theory", DSMBs or Data Monitoring committees(IRBs) have been known to suggest to the sponsor the stopping of a clinical trial because the results are so clear(good) from an efficacy standpoint that it would be pointless to continue the trial.
Possible explanation? PFE is investing multiple millions of $$$ in companies with products solving unmet needs:
https://ih.advfn.com/stock-market/NYSE/pfizer-PFE/stock-news/91592778/flagship-pioneering-and-pfizer-partner-to-accelera
"CAMBRIDGE, Mass. and NEW YORK, July 18, 2023 /PRNewswire/ -- Flagship Pioneering, Inc. and Pfizer Inc. (NYSE: PFE) today announced the companies have partnered to create a new pipeline of innovative medicines. Under the terms of the novel agreement, Flagship and Pfizer will each invest $50M upfront to explore opportunities to develop 10 single-asset programs by leveraging Flagship's ecosystem of more than 40 human health companies and multiple biotechnology platforms. Pfizer will fund and have an option to acquire each selected development program. Flagship and its bioplatform companies will be eligible to receive up to $700M in milestones and royalties for each successfully commercialized program.
Pioneering Medicines, an initiative of Flagship Pioneering, working in collaboration with Pfizer's research and development leadership, will lead the exploration process to drive rapid potential portfolio creation. The focus will be addressing unmet needs within Pfizer's core strategic areas of interest, including in broad patient populations and diseases with high potential to benefit from a diverse range of technology platforms and modalities.
"Flagship and Pfizer enter into this strategic alliance driven by a shared sense of urgency to develop novel medicines that make a difference for patients," said Paul Biondi, President, Pioneering Medicines, and Executive Partner, Flagship Pioneering. "This new partnership brings together the best of our organizations to maximize discovery and development potential from inception to impact through a unique innovation supply chain that sets us on a path to potentially realize transformational medicines more quickly and effectively."
"At Pfizer, we are expanding our efforts to pursue potential breakthrough science with unique approaches and funding mechanisms designed to leverage the dynamic scientific ecosystem," said Mikael Dolsten, M.D., Ph.D., Chief Scientific Officer and President, Worldwide Research, Development and Medical of Pfizer. "This collaboration is an exciting opportunity for Pfizer to bring deep scientific expertise and apply our development and regulatory strength to Flagship's diverse portfolio of technology platforms, translating early-stage innovation to potential medicines."
Last week Roche, and today Argenx. Both supply chains feeding into HALO should help CDMO share price, assuming CDMO continues as the feed.
https://ih.advfn.com/stock-market/NASDAQ/halozyme-therapeutics-HALO/stock-news/91579202/positive-topline-data-reported-from-argenxs-adhere
https://invest.ameritrade.com/grid/p/site#r=jPage/https://research.ameritrade.com/grid/wwws/research/stocks/news/article?c_name=invest_VENDOR&docKey=1-DN20230713010014-010014
JNJ has an aggressive new management team also; the WSJ reports today that it has sued 4 doctors in Federal Courts in New Jersey and California who are alleged to have published numerous articles with false information about the company's talc baby powder supposedly containing asbestos, causing damage to JNJ's earnings and reputation. In a war of experts, JNJ has won nearly all suits filed by numerous plaintiffs, but lost a few that resulted in multi-millions of $$$ damages.
Dr. Bhatt has called the MO allegations "silly'.
https://ih.advfn.com/stock-market/NASDAQ/22nd-century-XXII/stock-news/91568407/new-to-the-street-tv-announces-episode-488-with-it
An aggressive new management team might try this kind of advertisement, hooking up with a sponsor who is interested in stopping, or reducing risk from, a CVD medical condition that kills more people than all cancers.
"22nd Century Group, Inc.'s (NASDAQ: XXII) ($XXII) CEO, James Mish, talks with New to The Street's TV Host Jane King. From the Nasdaq MarketSite studio, James explains the Company's business in plant-based biotechnologies that creates health and wellness products, particularly reducing nicotine tobacco and advancing cannabinoid ingredients. The Company's tobacco product, the VLN® cigarettes, is the first and only 95% reduced nicotine tobacco product with an FDA Modified Risk Tobacco Product (MRTP) authorization. James explains how cigarettes help curb smoking habits to get people to stop smoking completely. Smoking less reduces the long-term harmful effects associated with tobacco. The FDA wants to ban menthol cigarettes and implement industry mandates to produce low-level nicotine tobacco products. James tells viewers the Company's cigarettes are the first of its kind in the marketplace, and the nicotine levels would be consistent with the FDA's forthcoming mandates. Clinical studies have shown that the VLN product can reduce smoking by about 60%, and the cigarette package states, "Helps You Stop Smoking." The tobacco industry is over $800B annually, so the Company plans to expand into other global markets and is currently doing operational pilot projects in Japan, Switzerland, and S. Korea. ....."
"This is a new formulation incorporating other drugs under the claim section which if you read it, you might better understand this isn't a Vasepa plus statin, but a brand new formulation which will need to be studied and will need FDA approval. It's a future generation and it will probably be given a new name because it will not be Vascepa, maybe"
You are correct....maybe, years from now. But the disclosure of the "new" patent discloses many other formulations that do not seem to be encompassed by, or recited in, the specific composition claims of the patent you have cited. Suppose some entity omits one or more ingredients mentioned in '820 claim 1 or other dependent claims, and chooses to explore other compositions disclosed in the '820 patent?
More interesting, perhaps, is what is disclosed and claimed in the many parent applications of the '820 patent that also have issued as patents( you do not cite). Those patents have application filing dates more than a decade ago; the '820 patent purports to be a continuation of each/all of them, meaning no new disclosure in the '820 application.
Thanks for the article and editorial. Very useful information and opinion in both.
Thanks, ebo. I haven't traveled west of Great Lakes either. Maybe a phone call or email to IR would elicit an answer to the question I posed. I agree the technology looks like something CDMO would or should have.
Does anybody know/remember whether this technology was installed in either of Avid's locations?:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172256294
While we see ANIP ascend nicely in share price, I suggest folks here take a look at RDGL. Its CEO bought a modest amount of shares a year ago. I bought a modest amount(35K) today myself. See post by 1hunglo on Biotech Value message board today for more what this micro-cap company is doing.
Its IsoPet division has a Yttrium-90 radioactive micro- particle gel being used to treat solid tumors in dogs, cats and horses at university veterinary hospitals. It has a RadioGel device in development to treat non-resectable tumors in humans at Mayo Clinic and Hopkins
With the right people in place, it doesn't take long to get to market. All here should recognize this company that a former CDMO BOD member went to:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172228821
Perhaps it is time for the new Amarin BOD, Sarissa/Denner and our acting CEO to implement or borrow an idea/event from elsewhere in the Middle East now that Vascepa is an approved medication in the Arab region.
The Saudi Public Investment Fund, PIF, added to its holdings in LCID, [reported by Al Root in Barron's yesterday]. PIF now owns ~65% of LCID common stock outstanding. The TV advertisements featuring advantages of LUCID autos have recently increased greatly on various network and sports channels. Can the Saudi fund be persuaded to invest in Amarin? An equity investment by PIF in Amarin would supply needed funds to renew educational media ads that used to appear regularly.
https://www.barrons.com/articles/saudi-investment-fund-buys-lucid-stock-c9eeb5a6
See also today's headlines from WRAP, whose product/service sales doubled in the past 6 months from appropriate broadcast of its educational ads to its potential customers.
Each of 244-247 are currently present here also.... too many $$$ are gone after this past week....most all of biotech, healthcare was minus.
Thanks for the info. We'll leave the subject there. Sounds like introducing a new drug and obtaining coverage in Canada is = in difficulty to Europe.
Email you can link? or was it a personal conversation or telephone call? I hold shares of HLS also, and I thought CaptBeer's idea was worth considering in search for a new Amarin CEO
I see nothing to support the reason you give for the HLS COB, former CEO, stepping down. It remains only your unsupported opinion in my view.
I have followed HLS, but do not have a source/link for the info you just posted. Vascepa sales in the HLS portfolio look good to me. Is that due only because PFE is now there?